Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy
Senti Bio advances SENTI-202 pivotal trial with Donor X selection strategy, achieving 50% complete remission in heavily pretreated R/R...
Alumis Reports 68% PASI 90 Response for Envudeucitinib in Psoriasis Trial
Alumis reports 68% PASI 90 response for envudeucitinib in psoriasis trial ONWARD1, matching deucravacitinib efficacy with early scalp clearance...
Cardiff Oncology Advances Onvansertib Phase 3 for RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology advances onvansertib Phase 3 for RAS-mutated metastatic colorectal cancer with 72.2% response rate in Phase 2 data.
NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Study
NBTXR3 achieves 57% complete response rate in stage III lung cancer study, compared to under 5% with current standard...
UroGen’s UGN-103 Shows 94.5% Response Rate in Phase 3 NMIBC Trial
UroGen's UGN-103 demonstrated 94.5% six-month response rate in Phase 3 NMIBC trial, edging prior standard ZUSDURI's efficacy benchmark.
Regeneron’s Fianlimab Misses Statistical Significance in Melanoma Trial
Regeneron's fianlimab melanoma trial missed statistical significance for progression-free survival, though the high-dose combination showed a 5.1-month numeric
The eCOA Vendor Stack You Built Is Already Obsolete
Signant Health's acquisition of Ametris on May 14 consolidates eCOA and wearable data streams—and exposes the real cost of...
The TOBRA Trial Just Killed a Widely Used Surgical Assumption — And Most Orthopedic Programs Haven’t Noticed Yet
A 1,660-patient RCT across 39 U.S. trauma centers found tobramycin adds nothing over vancomycin alone for preventing deep SSIs...
BioXcel Awaits FDA Decision on IGALMI At-Home Label Expansion
BioXcel awaits FDA decision on IGALMI at-home label expansion with November 14 PDUFA date. Approval would enable first outpatient...
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial
Alumis' envudeucitinib achieved 68% PASI 90 in Phase 3 psoriasis trial, exceeding typical oral TYK2 inhibitor benchmarks of 50–55%.